what is semaglutide face How to Avoid Ozempic While Using Weight Loss Injections (Semaglutide & Tirzepatide) Ozempic Face

In Lilly's 2026 TRIUMPH-1 Phase 3 readout, the primary body-weight endpoint was measured at 80 weeks, with extension data running to 104 weeks

Clinical research suggests that tirzepatide may produce greater average weight loss for some individuals, likely because it activates two metabolic hormone pathways instead of one

FDA-approved indications require either a BMI of 30+ or BMI of 27+ with comorbidities for weight management, or a type 2 diabetes diagnosis for the diabetes formulations

However, in our practice, both medications have been successful in helping patients with type 2 diabetes manage their blood sugar and achieve weight loss

Runny nose and nasal congestion are not listed as common side effects in clinical trials of semaglutide, yet some patients report these symptoms during GLP-1 treatment

Case report data show salivary flow returning to normal within four weeks of stopping semaglutide